Bionano Genomics Inc (NASDAQ:BNGO) has a beta value of 2.34 and has seen 3.0 million shares traded in the last trading session. The BNGO stock price is -713.51% off its 52-week high price of $3.01 and 16.22% above the 52-week low of $0.31. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.5 million shares traded. The 3-month trading volume is 1.59 million shares.
The consensus among analysts is that Bionano Genomics Inc (BNGO) is Buy stock at the moment, with a recommendation rating of 2.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bionano Genomics Inc (NASDAQ:BNGO) trade information
Over the past 30 days, the shares of Bionano Genomics Inc (NASDAQ:BNGO) have changed -18.48%. Short interest in the company has seen 6.07 million shares shorted with days to cover at 4.96.
Wall Street analysts have a consensus price target for the stock at $2, which means that the shares’ value could jump 81.5% from current levels. The projected low price target is $1.0 while the price target rests at a high of $175.0. In that case, then, we find that the current price level is -47197.3% off the targeted high while a plunge would see the stock gain -170.27% from current levels.
Bionano Genomics Inc (BNGO) estimates and forecasts
Figures show that Bionano Genomics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -62.14% over the past 6 months, with this year growth rate of 71.99%, compared to 17.40% for the industry. Revenue growth from the last financial year stood is estimated to be -2.00%.
4 analysts offering their estimates for the company have set an average revenue estimate of 7.85M for the current quarter. 4 have an estimated revenue figure of 10.98M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 23.59% over the past 5 years.
BNGO Dividends
Bionano Genomics Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Bionano Genomics Inc (NASDAQ:BNGO)’s Major holders
Insiders own 0.14% of the company shares, while shares held by institutions stand at 11.76% with a share float percentage of 11.78%. Investors are also buoyed by the number of investors in a company, with Bionano Genomics Inc having a total of 69.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Jun 30, 2024 , the former fund manager holds about 1.59% shares in the company for having 1.36 shares of worth $0.5 million while later fund manager owns 505.29 shares of worth $0.19 million as of Jun 30, 2024 , which makes it owner of about 0.59% of company’s outstanding stock.
